National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 3) (PB 28 of 2015)

Overview

The National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 3) (PB 28 of 2015) amends the National Health Determination under paragraph 98C(1)(b) of the National Health Act 1953 (the Act), which was initially established in 2008. This legislative instrument updates the conditions for Commonwealth payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners, in line with the changes introduced by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 3), effective from 1 April 2015. The amendments made by this instrument primarily involve the removal of a specific form of a drug from Schedule 4 of the Principal Determination. The objective of the Act, as established by Part VII, is to ensure the provision of reliable, timely, and affordable access to a wide range of medicines for all Australians through the Pharmaceutical Benefits Scheme (PBS). The Australian Parliament enacted this amendment to ensure that the PBS remains responsive to new medical evidence and technological advancements, thereby continuing to support the progressive realisation of the highest attainable standard of physical and mental health as recognised by the International Covenant on Economic, Social and Cultural Rights (ICESCR). The Pharmaceutical Benefits Advisory Committee (PBAC), an independent body comprising experts from various healthcare sectors, plays a crucial role in advising the Minister on which medicines should be subsidised. This collaborative approach ensures that decisions regarding the PBS are evidence-based and aligned with human rights principles.

Scope and Application

The National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 3) modifies the conditions for Commonwealth payments regarding the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners, as stipulated under the National Health Act 1953. This legislative instrument applies to entities and individuals involved in the supply of pharmaceutical benefits, specifically those approved by the Commonwealth to participate in the Pharmaceutical Benefits Scheme (PBS). The geographic reach of this Act is national, operating under the jurisdiction of the Commonwealth of Australia. It specifically excludes any entities or individuals not approved under the PBS. The determination extends its application through subordinate instruments, as outlined in the Principal Determination (PB 119 of 2008). The Amendment Determination removes polyvinyl alcohol in the form of eye drops 30 mg per mL, 15 mL from Schedule 4 of the Principal Determination, reflecting the changes made by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 3), effective from 1 April 2015. The changes are based on recommendations from the Pharmaceutical Benefits Advisory Committee, which ensures that decisions about pharmaceutical benefits are evidence-based and aligned with human rights standards.

Key Provisions

The National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 3) amends the National Health Determination under paragraph 98C(1)(b) of the National Health Act 1953 (the Act). Specifically, Schedule 4 of the Principal Determination, which lists the pharmaceutical benefits eligible for Commonwealth payments, is altered by the removal of polyvinyl alcohol in the form of eye drops, 30 mg per mL, 15 mL (section 1(1)). This change takes effect from 1 April 2015. The primary purpose of this Amendment Determination is to update the conditions under which payments are made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners, as stipulated in paragraph 98C(1)(b) of the Act. The Act imposes several obligations on the parties involved. Approved pharmacists and approved medical practitioners must adhere to the updated conditions outlined in the Amendment Determination to be eligible for Commonwealth payments for the supply of pharmaceutical benefits. This includes ensuring that the supply of pharmaceutical benefits complies with the revised list of eligible items as per Schedule 4. The Minister for Health, through this determination, sets out the specific conditions that must be met for the Commonwealth to make payments for pharmaceutical benefits, and these conditions must be followed by the approved practitioners. Breach of the conditions specified in the Amendment Determination may lead to civil or criminal consequences. The specific penalties for non-compliance are not detailed in the Amendment Determination but generally, any failure to comply with the provisions of the National Health Act 1953 could result in legal action against the non-compliant parties. In the context of the Pharmaceutical Benefits Scheme, penalties might include fines, recovery of payments made under the scheme, or other administrative actions. While the exact penalties are not outlined in this particular Amendment Determination, they would typically be governed by other sections of the National Health Act 1953 or related legislation.